Description: Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Home Page: www.codexis.com
200 Penobscot Drive
Redwood City,
CA
94063
United States
Phone:
650 421 8100
Officers
| Name | Title |
|---|---|
| Dr. Stephen George Dilly MBBS, Ph.D. | President, CEO & Chairman |
| Mr. Kevin Norrett M.B.A., M.S. | Chief Operating Officer |
| Dr. Alison Moore Ph.D. | Chief Technology Officer |
| Ms. Georgia L. Erbez | Chief Financial Officer |
| Ms. Carrie McKim | Director of Investor Relations |
| Ms. Karen Frechou-Armijo | Senior VP & Head of Human Resources |
| Dr. Stefan Lutz Ph.D. | Senior Vice President of Research |
| Mr. John Schiffhauer | Senior Vice President of Intellectual Property |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 138.8889 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.2037 |
| Price-to-Sales TTM: | 5.5989 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 174 |